Skip to content

Study on the Combined Use of Jiawei Xiaoqinglong Decoction and Conventional Western Medical Treatment for the Acute Exacerbation Period of Chronic Obstructive Pulmonary Disease (COPD) with an Exterior Cold and Interior Phlegm Pattern

Department of Respiratory and Critical Care Medicine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001026
Enrollment
Unknown
Registered
2026-04-20
Start date
2024-07-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Interventions

Test group:Jiawei Xiaoqinglong Decoction + conventional Western medicine treatment ? ?

Sponsors

Guangdong Second Provincial Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria of Western medicine, with severity classified as Grade I or Grade II: namely the non-respiratory failure group and the acute respiratory failure–non-life-threatening group. 2) Meet the diagnostic criteria of traditional Chinese medicine, with syndrome differentiation of external cold and internal fluid retention. 3) Aged 40 to 80 years, regardless of gender. 4) Subjects have given informed consent and signed the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1) Patients with bronchiectasis, cystic fibrosis, pulmonary tuberculosis, or lung cancer. 2) Patients with concomitant severe cardiovascular or cerebrovascular diseases, hepatic or renal insufficiency, rheumatic immune diseases, coagulation disorders, malignant tumors, or other underlying diseases. 3) Patients requiring invasive mechanical ventilation; patients with clinically confirmed or highly suspected pulmonary embolism. 4) Patients with a history of mental illness, alcoholism, or drug abuse. 5) Patients with allergic constitution, or those allergic to the study drugs or related treatments. 6) Pregnant or lactating women, and women during menstruation. 7) Patients whose liver function (ALT, AST) or renal function (serum creatinine) exceeds twice the upper limit of normal. 8) Individuals who have participated in or are currently participating in other clinical trials within the past 3 months. 9) Patients who refuse to take traditional Chinese medicine.

Design outcomes

Primary

MeasureTime frame
Total effective rate;Change in BCSS score on Day 7 relative to baseline;

Secondary

MeasureTime frame
TCM Syndrome Score;Inflammatory markers;Arterial blood gas (ABG);Pulmonary function: FEV1, FVC, FEV1/FVC%;6-Minute Walk Test (6MWT) ;COPD Assessment Test score;Length of hospital stay;Incidence of endotracheal intubation during hospitalization;

Countries

China

Contacts

Public ContactZhao Liyun

Guangdong Second Provincial Traditional Chinese Medicine Hospital

18602061889@163.com18602061889

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026